TTY Biopharm Company Limited (TPEX:4105)

Market Cap	18.25B -3.7%
Revenue (ttm)	6.51B +7.2%
Net Income	1.61B +3.3%
EPS	6.15 -1.8%
Shares Out	248.65M
PE Ratio	11.94
Forward PE	n/a
Dividend	4.50 (6.13%)
Ex-Dividend Date	Mar 26, 2026

Volume	634,942
Open	73.10
Previous Close	73.00
Day's Range	73.10 - 73.90
52-Week Range	71.60 - 87.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2025, TTY Biopharm Company's revenue was 6.45 billion, an increase of 9.49% compared to the previous year's 5.89 billion. Earnings were 1.56 billion, an increase of 7.55%.